JPRN-UMIN000003489已完成1 期
A phase I clinical study of cancer vaccine with MAGE-A4/Survivin helper peptide for patients with advanced cancers expressing MAGE-A4 or Survivin antigen - Cancer vaccine study with MAGE-A4/Survivin helper peptide
Department of General Surgery, Hokkaido University Graduated School of Medicine0 个研究点目标入组 12 人开始时间: 2010年4月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Pregnant women or refuse anticonception during the study (both sexes) 2) Lactating women 3) Severe bleeding disorders, meeting the criteria below; PT<50% APTT>60sec Fbg<100mg/dl FDP>20mg/ml 4) Active infection (HIV, HBV or HCV etc.) 5) Severe heart disease (NYHA class 3 or 4) 6) Autoimmune disease (scleroderma, Sjogren's syndrome, idiopathic thrombocytopenic purpura, multiple sclerosis, rheumatoid arthritis etc.) 7) Systemic administration of corticosteroid or immunosuppresive drugs during the study (Except local administration, inhaled drugs, and antiphlogistic analgetics). 8) Patient with impaired mental status in the study. 9) Inappropriate for study entry judged by an attending physician
研究者
相似试验
已完成
不适用
A phase I clinical trial of cancer vaccine using multiple antigen epitope peptides for advanced cervical canceradvanced and recurrent cervical cancerJPRN-UMIN000003999Saitama medical university international medical center18
已完成
1 期
The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigeIntractable malignant tumors expressing MAGE-A4 antigenJPRN-UMIN000001999Department of Surgical Oncology, Hokkaido University Graduate School of Medicine18
已完成
2 期
A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent colorectal cancersSurvivin-expressing advanced/recurrent colorectal cancer patients or patients who refuse standard cancer therapyJPRN-UMIN000007506Department of Gastroenterological Surgery I, Hokkaido University Graduated School of Medicine35
已完成
2 期
A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent breast cancersA phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent breast cancersJPRN-UMIN000007507Department of Breast and Endocrine Surgery, Hokkaido University Hospital40
已完成
1 期
A phase I study of cancer vaccine with CHP-MAGE-A4 in patients with advanced cancers expressing MAGE-A4 antigeAdvanced esophageal cancer, stomach cancer, non-small cell lung cancer (NSCLC), colon cancer.JPRN-UMIN000003188Department of Surgery Osaka University Graduate School of Medicine20